A patient has died following treatment with Sarepta’s gene therapy Elevidys, which treats muscular dystrophy. The 27% drop in the company’s shares comes after the patient suffered acute liver injury, a known side effect of the therapy. Although the severity of this case had not been seen before, Sarepta says it plans to update the prescribing information for Elevidys. This is the first reported patient death linked to the therapy, which has treated over 800 patients since its approval in 2023.
Source: https://apnews.com/article/sarepta-death-patient-duchennes-muscular-dystrophy-7ee6fc7b1e5e70667c638b598145a5f9